Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Gastroenterology"
DOI: 10.1007/s00535-017-1348-8
Abstract: BackgroundBiomarkers predicting the response to the anticancer treatment and prognosis in patients with advanced hepatocellular carcinoma (HCC) are required. Recently, high mobility group box 1 (HMGB1) was reported to promote HCC progression and be associated… read more here.
Keywords: serum hmgb1; prognosis; treatment; hmgb1 concentrations ... See more keywords